AHI Journal台康生技入選經濟部A+計畫開發皮下注射製劑 聚陽結盟宏達電跨足智慧穿戴EirGenix Tapped for MOEA A+ Project on Subcutaneous Delivery; Makalot Partners with HTC on Smart Wearables
經濟部核准 4 項前瞻研發計畫，台康生技建立皮下注射平台，聚陽與宏達電推進智慧體感服飾驗證。The Ministry of Economic Affairs approves four forward-looking R&D projects, backing EirGenix's subcutaneous platform and Makalot's sensory apparel validation with HTC.
前情提要Previously本刊第 6 次談Our take #6 on 生技醫療業
本篇重點：The key points:
- 經濟部審議通過台康生技、聚陽、采鈺與愛國者綠能等 4 項A+計畫MOEA approves four A+ projects including EirGenix, Makalot, VisEra, and Patriot Green Energy
- 台康生技切入高濃度皮下注射製劑平台，開發國產透明質酸酶技術EirGenix expands into high-concentration subcutaneous delivery, developing domestic hyaluronidase technology
- 聚陽攜手宏達電與翰沃生電，推進次世代穿戴式智慧體感服飾場域驗證Makalot partners with HTC and Hanvon to advance field verification for next-generation smart sensory apparel
- 泰福CDMO簽約澳洲Q-Sera，藥華藥舉行ET醫學專題演講拓展國際市場Tanvex CDMO signs with Australia's Q-Sera, while PharmaEssence hosts an ET medical symposium to expand international reach
經濟部產業技術司於第 12 次決審會議審議通過 4 項A+企業創新研發淬鍊計畫，台康生技與聚陽名列其中。這項政策補助將台康生技的技術線延伸至透明質酸酶與高濃度皮下注射製劑平台，同時聚陽攜手宏達電跨足智慧體感穿戴服飾驗證，顯示生醫與智慧穿戴供應鏈正往高附加價值製程推進。The Ministry of Economic Affairs' Department of Industrial Technology has approved four projects under its A+ Industrial Innovation R&D Program during its 12th final review meeting, with EirGenix and Makalot among the recipients. This government subsidy extends EirGenix's technology roadmap into hyaluronidase and high-concentration subcutaneous delivery platforms, while Makalot partners with HTC to validate smart sensory apparel, highlighting how biomedical and smart wearable supply chains are migrating toward higher-value-added processes.
台康生技（6589）EirGenix (6589)
經濟部產業技術司於第 12 次決審會議中，審議通過台康生技投入的「高體積／高濃度皮下注射製劑平台研發計畫」。該計畫聚焦國產透明質酸酶及高體積、高濃度皮下注射製劑平台技術開發，主要目標為突破人源化、高穩定性及無動物性原料製程等關鍵技術瓶頸。In its 12th final review meeting, the Ministry of Economic Affairs' Department of Industrial Technology approved EirGenix's "High-Volume / High-Concentration Subcutaneous Injection Formulation Platform R&D Project." The initiative focuses on domestic hyaluronidase alongside high-volume, high-concentration subcutaneous formulation platforms, aiming to clear key technical bottlenecks including humanization, high stability, and animal-origin-free manufacturing.
隨著生物製劑由靜脈注射逐步朝皮下注射發展，台康生技藉由建立透明質酸酶搭載抗體藥物之皮下注射製劑平台，提升藥物於皮下組織之擴散與吸收效率。該技術可延伸應用於抗體藥物、長效蛋白及慢性疾病藥品開發，並將提供國內生技製藥業者及CDMO製劑開發服務，以降低關鍵原料與技術對國外供應之依賴。As biologics transition from intravenous infusions to subcutaneous injections, EirGenix aims to pair hyaluronidase with antibody therapeutics to improve drug dispersion and absorption in subcutaneous tissue. The platform can be extended to antibody drugs, long-acting proteins, and chronic disease therapies, while offering formulation CDMO services to domestic biopharma firms to lower reliance on foreign supply for critical inputs and technologies.
聚陽（1477）Makalot (1477)
成衣代工廠聚陽實業同樣通過經濟部「A+企業創新研發淬鍊計畫」審查，其執行項目為「次世代穿戴式智慧體感服飾整合開發暨多元場域驗證」。面對體感科技與沉浸式應用發展，聚陽本次攜手宏達電（2498）以及翰沃生電科技共同推動研發。Apparel manufacturer Makalot Industrial also cleared review under the MOEA A+ Industrial Innovation R&D Program for its "Next-Generation Wearable Smart Sensory Apparel Integration and Multi-Scenario Field Validation" project. In response to immersive and sensory technology trends, Makalot has partnered with HTC (2498) and Hanvon to advance development.
外部研究報告對於聚陽 2026 年獲利表現，共有 2 家機構提出預估，EPS預估區間落在 15.57 元至 16.02 元之間。該計畫旨在藉由智慧穿戴與生醫感測之整合，推動傳統成衣代工跨足高階智慧體感應用市場。Two external research institutions have issued earnings forecasts for Makalot in 2026, projecting EPS between NT$15.57 and NT$16.02. The project aims to integrate smart wearables with biomedical sensing, enabling the traditional garment manufacturer to enter high-end sensory application markets.
其他要聞Other Developments
藥華藥（6446）今日舉行ET醫學專題演講慶祝午宴，副總統蕭美琴出席並肯定其新藥自主研發走向國際成果；泰福-KY（6541）旗下Bora Biologics則簽訂長期供貨協議供應重組RAPClot蛋白，持續推展商業化供應鏈。PharmaEssence (6446) hosted a celebratory luncheon today for an ET medical symposium, with Vice President Bi-khim Hsiao attending and praising its proprietary drug R&D expansion into overseas markets; Tanvex BioPharma (6541) subsidiary Bora Biologics entered into a long-term supply agreement to produce recombinant RAPClot protein, continuing to broaden its commercial supply chain.
本刊觀點：The Journal's View: 生技醫療與跨領域智慧應用正由單純產能擴充轉向核心製劑技術與跨界硬體整合。今天新增的事實是經濟部A+計畫正式核准台康生技的高體積皮下注射平台及聚陽的體感服飾驗證，兩者皆取得政策性研發資源支持。
本刊認為，市場當前的共識聚焦於生物製劑CDMO產能開出與新藥海外商業化營收，但數據呈現的裂縫在於：台康生技雖然獲得皮下注射平台專案支持，惟外部機構對其關鍵效益多寄望於中長期的技術授權與委託服務，該項人源化透明質酸酶技術目前仍處於研發起步階段，尚未轉化為實質營收貢獻。
已經發生的事實是新廠產線與政策專案陸續拍板，尚未被證實的是皮下注射新劑型能否在國外既有專利壁壘下順利完成商業化驗證並被大型藥廠採用。
Biomedical and cross-disciplinary smart applications are shifting away from pure capacity expansions toward core formulation technologies and cross-sector hardware integration.
The incremental development today is the MOEA A+ Program's formal approval of EirGenix's high-volume subcutaneous injection platform and Makalot's sensory apparel validation, both securing policy-backed R&D resources.In the Journal's view, the current market consensus focuses on biologic CDMO capacity rollouts and overseas commercial revenue from new drugs.
However, the fracture in the data lies here: although EirGenix has secured project backing for a subcutaneous platform, institutional expectations largely tie its key benefits to mid- to long-term licensing and contract services; this humanized hyaluronidase technology remains in early-stage R&D and has yet to translate into meaningful revenue.
What has occurred is the gradual finalization of new production lines and state-backed projects; what remains unverified is whether new subcutaneous formulations can clear existing overseas patent thickets, finish commercial validation, and win adoption by major pharmaceutical firms.
接下來看什麼：What to watch:
- 台康生技皮下注射製劑平台研發里程碑：透明質酸酶無動物性原料製程若於 2026-11-30 前完成實驗室階段驗證，代表自主平台建立順利；若延宕則代表人源化技術難度高於預期EirGenix subcutaneous formulation platform R&D milestones: If animal-origin-free hyaluronidase process completes lab validation before 2026-11-30, proprietary platform development remains on track; delays would suggest humanization technical hurdles are higher than anticipated
- 聚陽智慧體感服飾專案進度：與宏達電合作之多元場域驗證若於 2026-12-10 前進入實體展示，代表跨界整合落地；若無具體進展則代表智慧穿戴商用轉化放緩Makalot smart sensory apparel project progress: If multi-scenario field validation with HTC enters live physical demonstrations before 2026-12-10, cross-sector commercial integration is taking hold; lack of concrete progress would signal slower commercialization for smart wearables
圖表與數字以公開行情與營收面板另行計算，行情資料日 2026-09-18。Charts and figures are computed from public price and revenue panels; market data as of 2026-09-18.
